Martin Sedlacek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Martin Sedlacek has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Brian D. Remillard
Dartmouth School of Medicine, Lebanon, NH
3 shared publicationsAnton C. Schoolwerth
2 shared publicationsArief A. Suriawinata
2 shared publicationsHimabindu Yerneni
Case Western Reserve University, Cleveland, Ohio (H.Y.).
2 shared publicationsAlan R. Schned
Department of Pathology Dartmouth-Hitchcock Medical Center Lebanon, NH, USA
1 shared publication- Altair Jacob Mocelin1 shared publication
Latest Publications
- 1 August 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 98 (2) , 112-114
A case of IgM nephropathy secondary to NSAIDs
- 1 August 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 98 (2) , 112-114
A case of IgM nephropathy secondary to NSAIDs
- 19 May 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (8) , 2491-2492
A 40‐year follow‐up of a patient with Graham–Boyle–Troxell syndrome
- 19 May 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (8) , 2491-2492
A 40‐year follow‐up of a patient with Graham–Boyle–Troxell syndrome
- 5 November 2021
- Published by Springer Nature in CEN Case Reports
- Vol. 11 (2) , 225-230
Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib
A 67-year-old woman with transverse myelitis and seizure disorder secondary to suspected central nervous system (CNS) systemic lupus erythematosus (SLE) and seropositive rheumatoid arthritis had two episodes of severe nephrotic syndrome 15 years apart. She underwent a renal biopsy in both episodes, showing tip lesion variant focal segmental glomerulosclerosis (FSGS). The patient responded both times to prednisone treatment, achieving a complete remission within 2 months in the first episode and remission 4 months in the second episode. A year after her second episode, the patient had a third episode of severe nephrotic syndrome. She achieved an equally rapid complete remission in 3 months without steroid treatment, as she was concomitantly treated with the Janus Kinase (JAK) inhibitor tofacitinib for a flare of rheumatoid arthritis. This case report suggests that JAK inhibitors may have therapeutic use in FSGS, which is supported by experimental data in the medical literature.
- 5 November 2021
- Published by Springer Nature in CEN Case Reports
- Vol. 11 (2) , 225-230
Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib
A 67-year-old woman with transverse myelitis and seizure disorder secondary to suspected central nervous system (CNS) systemic lupus erythematosus (SLE) and seropositive rheumatoid arthritis had two episodes of severe nephrotic syndrome 15 years apart. She underwent a renal biopsy in both episodes, showing tip lesion variant focal segmental glomerulosclerosis (FSGS). The patient responded both times to prednisone treatment, achieving a complete remission within 2 months in the first episode and remission 4 months in the second episode. A year after her second episode, the patient had a third episode of severe nephrotic syndrome. She achieved an equally rapid complete remission in 3 months without steroid treatment, as she was concomitantly treated with the Janus Kinase (JAK) inhibitor tofacitinib for a flare of rheumatoid arthritis. This case report suggests that JAK inhibitors may have therapeutic use in FSGS, which is supported by experimental data in the medical literature.
- 6 July 2021
- Published by Wiley in Hemodialysis International
- Vol. 26 (1) , E12-E15
The dietary supplement chitosan lowers serum phosphorus in a hemodialysis patient not tolerating prescription medications
Chitosan is a widely available, nontoxic, biodegradable biopolymer that binds negatively charged molecules. Its use as a dietary supplement for weight loss derives from its purported ability to bind negatively charged lipids and bile acids and prevent their gastrointestinal absorption. Here, we report the case of a dialysis patient who did not tolerate prescription phosphorus binders and who has been able to control her serum phosphorus levels for a year by taking 3.5 g of chitosan a day with meals. A quantitative analysis shows that chitosan may bind between 16 and 41 mg of phosphorus per gram, comparable to prescription binders. Chitosan may provide an over‐the‐counter alternative as non‐calcium phosphorus binder for patients not tolerating prescription phosphorus binders because of side effects, cost, or efforts to limit their medication burden.
- 6 July 2021
- Published by Wiley in Hemodialysis International
- Vol. 26 (1) , E12-E15
The dietary supplement chitosan lowers serum phosphorus in a hemodialysis patient not tolerating prescription medications
Chitosan is a widely available, nontoxic, biodegradable biopolymer that binds negatively charged molecules. Its use as a dietary supplement for weight loss derives from its purported ability to bind negatively charged lipids and bile acids and prevent their gastrointestinal absorption. Here, we report the case of a dialysis patient who did not tolerate prescription phosphorus binders and who has been able to control her serum phosphorus levels for a year by taking 3.5 g of chitosan a day with meals. A quantitative analysis shows that chitosan may bind between 16 and 41 mg of phosphorus per gram, comparable to prescription binders. Chitosan may provide an over‐the‐counter alternative as non‐calcium phosphorus binder for patients not tolerating prescription phosphorus binders because of side effects, cost, or efforts to limit their medication burden.
- Open Access
- 12 June 2021
- Published by Hindawi Limited in International Journal of Nephrology
- Vol. 2021, 1-5
Renal Effects of Hyperbaric Oxygen Therapy in Patients with Diabetes Mellitus: A Retrospective Study
Hyperbaric oxygen therapy (HBOT) is an adjunctive treatment for patients with diabetic foot ulcers. The prolonged high oxygen level used in HBOT can produce oxidative stress, which may be harmful to the kidney. Animal experiments suggest HBOT does not harm renal function and may have an antiproteinuric effect, but little is known on the effect of HBOT in humans. We performed a retrospective chart review of 94 patients with diabetes mellitus who underwent HBOT at our institution over an eight-year period. Thirty-two patients had serum creatinine levels within 60 days of the start and the end of treatment. Creatinine levels were 1.41 ± 0.89 mg/dl before and 1.52 ± 1.17 mg/dl after hyperbaric treatments with no statistically significant difference (mean (postcreatinine + precreatinine/2) = 0.10 mg/dl, SE = 0.11, t = 0.89). Twenty-three patients had proteinuria measurements before and after HBOT mainly by urine dipstick analysis. A Wilcoxon signed-rank test showed less proteinuria after HBOT than before (N = 23, p = 0.002 ). Proteinuria was absent in 7 of 23 patients (30%) before HBOT and 13 of 23 patients (57%) after HBOT, a reduction by almost 50%. This observation is remarkable because oxidative stress might be expected to increase rather than decrease proteinuria.
- 12 June 2021
- Published by Hindawi Limited in International Journal of Nephrology
- Vol. 2021, 1-5
Open AccessRenal Effects of Hyperbaric Oxygen Therapy in Patients with Diabetes Mellitus: A Retrospective Study
Hyperbaric oxygen therapy (HBOT) is an adjunctive treatment for patients with diabetic foot ulcers. The prolonged high oxygen level used in HBOT can produce oxidative stress, which may be harmful to the kidney. Animal experiments suggest HBOT does not harm renal function and may have an antiproteinuric effect, but little is known on the effect of HBOT in humans. We performed a retrospective chart review of 94 patients with diabetes mellitus who underwent HBOT at our institution over an eight-year period. Thirty-two patients had serum creatinine levels within 60 days of the start and the end of treatment. Creatinine levels were 1.41 ± 0.89 mg/dl before and 1.52 ± 1.17 mg/dl after hyperbaric treatments with no statistically significant difference (mean (postcreatinine + precreatinine/2) = 0.10 mg/dl, SE = 0.11, t = 0.89). Twenty-three patients had proteinuria measurements before and after HBOT mainly by urine dipstick analysis. A Wilcoxon signed-rank test showed less proteinuria after HBOT than before (N = 23, p = 0.002 ). Proteinuria was absent in 7 of 23 patients (30%) before HBOT and 13 of 23 patients (57%) after HBOT, a reduction by almost 50%. This observation is remarkable because oxidative stress might be expected to increase rather than decrease proteinuria.
- 18 August 2020
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (4) , 315
Metabolic Alkalosis and Cystic Fibrosis: A Case Report
- 18 August 2020
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 173 (4) , 315
Metabolic Alkalosis and Cystic Fibrosis: A Case Report
- 1 October 2019
- Published by Elsevier in Kidney International
- Vol. 96 (4) , 1041
Reverse corticomedullary differentiation in acute cortical necrosis
- 1 October 2019
- Published by Elsevier in Kidney International
- Vol. 96 (4) , 1041
Reverse corticomedullary differentiation in acute cortical necrosis
- Open Access
- 4 May 2011
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 4 (5) , 352
Smiling glomerulus reveals diagnosis in seronegative anti-glomerular basement membrane disease
A 58-year-old woman with a history of tobacco use and chronic obstructive pulmonary disease was urgently referred by her family doctor for coffee-colored urine and swollen ankles since 2 days. The serum creatinine was 3.3 mg/dL, having increased from 0.9 mg/dL 1 month before. Blood pressure was 116/54 mmHg. The urine sediment showed acanthocytes and red cell casts and protein/creatinine ratio was 1.2. The chest X-ray showed no focal infiltrate. The patient was hospitalized and a renal biopsy was performed. Light microscopy revealed a focal necrotizing glomerulonephritis with crescent formation but only 2 of 14 glomeruli were sclerotic. Immunofluorescence showed linear staining for IgG in all seven evaluable glomeruli. There was a ‘smiley’-like picture in one glomerulus (Figure 1). No deposits were found on electron microscopy. A diagnosis of anti-glomerular basement membrane disease (anti-GBM disease) was made and the patient was treated with steroids, cyclophosphamide and plasmapheresis. Testing for anti-GBM antibodies was negative in two different reference laboratories; thus, it would have been impossible to make the correct diagnosis without a biopsy. Published data indicates that serology is negative in up to 13% of cases of biopsy-proven anti-GBM disease [1].
- 4 May 2011
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 4 (5) , 352
Open AccessSmiling glomerulus reveals diagnosis in seronegative anti-glomerular basement membrane disease
A 58-year-old woman with a history of tobacco use and chronic obstructive pulmonary disease was urgently referred by her family doctor for coffee-colored urine and swollen ankles since 2 days. The serum creatinine was 3.3 mg/dL, having increased from 0.9 mg/dL 1 month before. Blood pressure was 116/54 mmHg. The urine sediment showed acanthocytes and red cell casts and protein/creatinine ratio was 1.2. The chest X-ray showed no focal infiltrate. The patient was hospitalized and a renal biopsy was performed. Light microscopy revealed a focal necrotizing glomerulonephritis with crescent formation but only 2 of 14 glomeruli were sclerotic. Immunofluorescence showed linear staining for IgG in all seven evaluable glomeruli. There was a ‘smiley’-like picture in one glomerulus (Figure 1). No deposits were found on electron microscopy. A diagnosis of anti-glomerular basement membrane disease (anti-GBM disease) was made and the patient was treated with steroids, cyclophosphamide and plasmapheresis. Testing for anti-GBM antibodies was negative in two different reference laboratories; thus, it would have been impossible to make the correct diagnosis without a biopsy. Published data indicates that serology is negative in up to 13% of cases of biopsy-proven anti-GBM disease [1].
- 1 February 2008
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 51 (2) , 302-306
Mucormycosis Peritonitis: More Than 2 Years of Disease-Free Follow-up After Posaconazole Salvage Therapy After Failure of Liposomal Amphotericin B
- 1 February 2008
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 51 (2) , 302-306
Mucormycosis Peritonitis: More Than 2 Years of Disease-Free Follow-up After Posaconazole Salvage Therapy After Failure of Liposomal Amphotericin B
- 23 August 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (8) , 806
“Maltese Crosses” in the Nephrotic Syndrome
Images in Clinical Medicine from The New England Journal of Medicine — “Maltese Crosses” in the Nephrotic Syndrome
- 23 August 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (8) , 806
“Maltese Crosses” in the Nephrotic Syndrome
Images in Clinical Medicine from The New England Journal of Medicine — “Maltese Crosses” in the Nephrotic Syndrome